- Post-Hoc: Lilly gets more secretive and hides Phase 1 pipelineEli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pr…Endpoints · 1mo ago↗ source
- Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks<figure><div><img src="https://imgproxy.divecdn.com/KkNxfSBTkY2VjB8ICSuee0jTuqLQfv0D9hMURCyAiqU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNDcyX1h1c…BioPharma Dive · 1mo ago↗ source
- AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…